Last reviewed · How we verify
Neither Pregabalin nor Gabapentin
It works by binding to voltage-gated calcium channels in the nervous system, reducing the release of pain-causing chemicals.
It works by binding to voltage-gated calcium channels in the nervous system, reducing the release of pain-causing chemicals. Used for Neuropathic pain, Fibromyalgia.
At a glance
| Generic name | Neither Pregabalin nor Gabapentin |
|---|---|
| Sponsor | CAMC Health System |
| Drug class | Anticonvulsant |
| Target | Voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Mechanism of action
Pain medications like this one work by blocking the flow of calcium ions into nerve cells, which reduces the release of pain-causing chemicals. This leads to a decrease in the transmission of pain signals to the brain.
Approved indications
- Neuropathic pain
- Fibromyalgia
Common side effects
- Dizziness
- Somnolence
- Headache
- Fatigue
- Nausea
- Dry mouth
- Weight gain
- Edema
- Arthralgia
- Muscle weakness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neither Pregabalin nor Gabapentin CI brief — competitive landscape report
- Neither Pregabalin nor Gabapentin updates RSS · CI watch RSS
- CAMC Health System portfolio CI